LifeStance CMO granted 115,107 RSUs

LifeStance Health Group, Inc. reported that Chief Medical Officer Stephanie Carin Eken acquired equity-based compensation in the form of restricted stock units.

Accepted by SEC EDGAR 03/09/2026 - 08:13 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

LifeStance Health Group, Inc. reported that Chief Medical Officer Stephanie Carin Eken acquired equity-based compensation in the form of restricted stock units. On March 5, 2026, she was granted 115,107 RSUs, each representing a contingent right to receive one share of LifeStance common stock.

The Form 4 classifies this as a grant or award acquisition at a price of $0.00 per share, typical for stock-based compensation. Following this grant, her directly held common stock and RSU-related interest totals 115,107 shares of LifeStance common stock on a contingent basis.

Insider Trade Summary

Grant/Award: 115,107 shares

Grant/Award 1 txn

Insider Eken Stephanie Carin

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	115,107	$0.00	$0.00

Holdings After Transaction: Common Stock — 115,107 shares (Direct)

Footnotes (1)

1. F1. Includes 115,107 restricted stock units ("RSUs") granted on March 5, 2026. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did LFST report for Stephanie Carin Eken?

LifeStance reported that Chief Medical Officer Stephanie Carin Eken received a grant of 115,107 restricted stock units on March 5, 2026. Each RSU represents a contingent right to receive one share of LifeStance common stock as part of her equity-based compensation.

How many LifeStance (LFST) shares are tied to the new RSU grant?

The grant covers 115,107 restricted stock units, each linked to one share of LifeStance common stock. In total, the award gives Stephanie Carin Eken a contingent right to receive 115,107 shares, subject to the RSU terms and conditions described in company plans.

Was cash paid for the LFST shares in Stephanie Carin Eken’s Form 4?

No cash changed hands in this transaction; the Form 4 shows a price per share of $0.00. This indicates the 115,107 restricted stock units were granted as compensation rather than purchased on the open market or through a cash-funded stock acquisition.

What is Stephanie Carin Eken’s direct ownership after this LFST RSU grant?

After the March 5, 2026 grant, Stephanie Carin Eken is reported as directly owning 115,107 shares tied to this award. These are structured as restricted stock units, each providing a contingent right to receive one share of LifeStance common stock under applicable award terms.

How does the Form 4 classify Stephanie Carin Eken’s LFST transaction?

The transaction is classified with code "A" as a grant, award, or other acquisition of non-derivative common stock. It reflects an equity compensation grant of 115,107 restricted stock units to the Chief Medical Officer, rather than a market purchase or sale of existing LFST shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Eken Stephanie Carin

(Last) (First) (Middle)

C/O LIFESTANCE HEALTH GROUP, INC.

4800 N. SCOTTSDALE ROAD, SUITE 2500

(Street)

SCOTTSDALE AZ 85251

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LifeStance Health Group, Inc. [ LFST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/05/2026		A		115,107(1)	A	$0	115,107	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes 115,107 restricted stock units ("RSUs") granted on March 5, 2026. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

	By: /s/ Ryan Pardo, Attorney-in-Fact	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.